Welcome to the May/June edition of HTB.
As usual, this is a very diverse issue, covering treatment news and advances for both high and low income countries.
Although we lead with anecdotal reports of side effects linked to generic abacavir, this is mainly for unexplained recent symptoms where this might be important to consider.
Conference news comes from three meetings and includes a review of the Option B+ programme in Malawi plus a pipeline from CROI on new ARVs.
ARV news includes new drug submissions and labelling safety updates, continued in journal reviews relating to HIV complications and pathogenesis.
This is the second issue of HTB that is only being distributed in electronic format.
This means that if you used to receive HTB by post, please register for electronic subscriptions to continue to receive HTB and other i-Base publications.
Please also consider helping with our funding appeal to support i-Base for the next year.